REDMOND, Wash.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that the company will demonstrate its Transoral Incisionless Fundoplication (TIF®) procedure at the 39th Annual New York Course, hosted by the New York Society for Gastrointestinal Endoscopy (NYSGE), December 17 – 18, 2015 at the New York Marriott Marquis Hotel in New York City.
Brian P. Bosworth, MD, and Jonathan Cohen, MD, will lead the hands-on demonstrations on Thursday, December 17 from 7:30 a.m. to 6 p.m. and Friday, December 18 from 7:30 a.m. to 4 p.m. The TIF procedure with EsophyX® device will be showcased at table six.
Additional presentations will mention data on the TIF procedure using EsophyX device during the event on December 17. The full course, “Endoscopy: Everyday, Extreme and Everything In Between,” will include the following highlights for gastroenterologists to attend:
- “Endoscopic Treatment of GERD” Anthony Starpoli, MD, New York gastroenterologist at Greenwich Village Gastroenterology; 1:50 p.m. to 2:05 p.m.
- Option 10: Gastrointestinal Motility - Presentation “Refractory GERD and pH Testing: Indications and Applications” Bani Chander Roland, MD, a gastroenterologist and director of the Center for Motility and Neurogastroenterology and Acid-Related (GERD) Disorders Program at New York-Presbyterian Hospital; course runs from 6 p.m. until 8:30 p.m.
“Many doctors throughout the country continue to see the long-term positive impact of the TIF procedure on patients suffering from chronic GERD,” said Skip Baldino, President and CEO of EndoGastric Solutions. “As the Category 1 CPT® code for the TIF procedure goes into effect in January of next year, more physicians will be able to provide the procedure as a viable treatment option for select GERD patients.”
EGS will exhibit at NYSGE booth #300.
About NYSGE
The New York Society for Gastrointestinal Endoscopy (NYSGE) was founded in 1974 by Drs. Henry Colcher, Howard J. Eddy Jr., Richard McCray, Paul Sherlock, Hiromi Shinya, Jerome D. Waye, Sidney J. Winawer and David S. Zimmon, with the goal of developing a New York working group of friends to teach each other and disseminate their collective knowledge of gastrointestinal endoscopy. Over the years, the Society has flourished and today is comprised of more than 300 attending members and over 200 fellows. NYSGE is the largest regional endoscopic society in the United States. To fulfill its mission of education and research, the Society hosts numerous seminars throughout the year, including an annual summer endoscopy course for new fellows, and sponsors the Annual New York Course, a major postgraduate endoscopy conference each December. NYSGE also endows the $10,000 Florence Lefcourt Award, which is presented for endoscopic research or community outreach initiatives. For further information, please visit www.nysge.org.
About Current Procedural Terminology (CPT®)
CPT codes are a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients, and third parties. CPT® is registered trademark of the American Medical Association.
EGS recently announced the Federal Register has posted coding and payment information specific to the new CPT® code, allowing patients to more easily receive access to treatment for GERD. Physicians and hospitals will be able to reference CPT Code 43210 EGD esophagogastric fundoplasty and APC 5331 Complex GI Procedures for TIF procedures as of January 1, 2016. The American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) jointly sponsored the CPT application.
About GERD
Gastroesophageal reflux disease (GERD) is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. The stomach produces hydrochloric acid and other digestive enzymes after a meal to aid in the digestion of food. The cells that line the stomach are coated with a protective mucus that can withstand gastric contents, while the cells that line the esophagus lack the same protection.
GERD is the most common gastrointestinal-related diagnosis made by physicians during clinical visits in the U.S. It is estimated that pain and discomfort from acid reflux impacts over 80 million people at least once per month in the U.S. The standard recommendations for symptomatic GERD patients include lifestyle changes (e.g., diet, scheduled eating times, and sleeping positions) and escalating doses of prescription medications for prolonged periods of time. Long-term, maximum-dose usage of prescription medications has been linked to a variety of other health complications.
About Transoral Incisionless Fundoplication (TIF®) procedure for reflux
Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair another treatment option to correct the underlying cause of GERD. Studies show that for up to three years after the TIF procedure esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily PPI medications to control symptoms.
Over 17,000 TIF patients have been treated worldwide since EsophyX® device clearance in 2007. More than 50 peer-review papers from over 40 centers have been published documenting consistent outcomes on over 800 unique study patients. For more information, visit www.GERDHelp.com.
About EsophyX® technology
The original EsophyX device was cleared by the FDA in 2007. EGS launched the third generation EsophyX device, the EsophyX Z in 2015. The technology has continued to evolve and is a clinically-backed tool for physician use in the treatment of GERD. The EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes–including low profile and larger high-definition models—to treat the underlying anatomical cause of GERD. The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope.
About EndoGastric Solutions®
Based in Redmond, WA, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a minimally invasive solution that addresses a significant unmet clinical need.
Indications:
The EsophyX device with SerosaFuse fasteners is indicated for use in transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia ≤ 2cm in size in patients with symptomatic chronic gastroesophageal reflux disease.
